Cargando…
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101935/ https://www.ncbi.nlm.nih.gov/pubmed/21487407 http://dx.doi.org/10.1038/bjc.2011.121 |
_version_ | 1782204325147181056 |
---|---|
author | Bozzetti, C Negri, F V Lagrasta, C A Crafa, P Bassano, C Tamagnini, I Gardini, G Nizzoli, R Leonardi, F Gasparro, D Camisa, R Capelli, S Silini, E M Ardizzoni, A |
author_facet | Bozzetti, C Negri, F V Lagrasta, C A Crafa, P Bassano, C Tamagnini, I Gardini, G Nizzoli, R Leonardi, F Gasparro, D Camisa, R Capelli, S Silini, E M Ardizzoni, A |
author_sort | Bozzetti, C |
collection | PubMed |
description | BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma. METHODS: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours. RESULTS: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results, available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic lymph node metastasis. CONCLUSION: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic process. |
format | Text |
id | pubmed-3101935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-31019352012-04-26 Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma Bozzetti, C Negri, F V Lagrasta, C A Crafa, P Bassano, C Tamagnini, I Gardini, G Nizzoli, R Leonardi, F Gasparro, D Camisa, R Capelli, S Silini, E M Ardizzoni, A Br J Cancer Clinical Study BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma. METHODS: The HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours. RESULTS: Concordance of FISH results, evaluable in 68 primary and matched metastatic sites, was 98.5%. Concordance of IHC results, available in 39 of the 72 paired cases, was 94.9%. Only one case showed discordance between primary tumour and metastasis, being negative by both IHC and FISH in the primary and showing HER2 overexpression and amplification in the corresponding pancreatic lymph node metastasis. CONCLUSION: The high concordance observed between HER2 results obtained by both IHC and FISH on primary tumours and corresponding metastases suggests that in gastric cancer HER2 status is maintained in most cases unchanged during the metastatic process. Nature Publishing Group 2011-04-26 2011-04-12 /pmc/articles/PMC3101935/ /pubmed/21487407 http://dx.doi.org/10.1038/bjc.2011.121 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Bozzetti, C Negri, F V Lagrasta, C A Crafa, P Bassano, C Tamagnini, I Gardini, G Nizzoli, R Leonardi, F Gasparro, D Camisa, R Capelli, S Silini, E M Ardizzoni, A Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title_full | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title_fullStr | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title_full_unstemmed | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title_short | Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma |
title_sort | comparison of her2 status in primary and paired metastatic sites of gastric carcinoma |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101935/ https://www.ncbi.nlm.nih.gov/pubmed/21487407 http://dx.doi.org/10.1038/bjc.2011.121 |
work_keys_str_mv | AT bozzettic comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT negrifv comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT lagrastaca comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT crafap comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT bassanoc comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT tamagninii comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT gardinig comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT nizzolir comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT leonardif comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT gasparrod comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT camisar comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT capellis comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT siliniem comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma AT ardizzonia comparisonofher2statusinprimaryandpairedmetastaticsitesofgastriccarcinoma |